Fundraising FoxForbion — 2023 Investments
8 investments dated 2023 · listed companies and verified rows first · show all
Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.
BiotechDeep TechHealthtech
Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)inKees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)
Co-investorsYsios CapitalNovartis Venture FundSunstone Capital
Co-investorsNeva Sgr.Sofinnova PartnersXGEN VentureAtlas VentureLongwood Fund
Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.
AI & Machine LearningEnterprise SoftwareSaaS
Co-investorsPebblebedAndera PartnersBGVFountain Healthcare PartnersHTGFPMV+2 more
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsBioGeneration VenturesCambridge Innovation CapitalGimvHadean VenturesSeroba Life SciencesBGV+2 more
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAccess BiotechnologyAtlas VentureNextech InvestAccess IndustriesRA Capital
Developing safe, long-lasting gene therapy treatments in a redosable, non-viral format.
Louis Breton(Founder)in
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Seamless TherapeuticsVectorY
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.